ArticleClinical and experimental pediatrics2022
Global varicella vaccination programs.
Article in Clinical and experimental pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Varicella Vaccine Effectiveness and Duration of Protection: A Systematic Review and Meta-Analysis.Journal of Korean medical science · 2025Pooled it
- Varicella-zoster virus seroprevalence among reproductive-age women in Iran: a meta-analysis and implications for targeted immunization.BMC infectious diseases · 2025Pooled it
- Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.Human vaccines & immunotherapeutics · 2026Trial
- Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in China.Human vaccines & immunotherapeutics · 2025Trial
- Global burden of varicella in children aged 5-9 y, relationship with vaccination policy indicators, and projected trends to 2030.Human vaccines & immunotherapeutics · 2026Article
- Safety, immunogenicity, and effectiveness of the MAV/06 varicella vaccine: A comprehensive review of a new strain vaccine.Human vaccines & immunotherapeutics · 2026Review
- Herpes Zoster Vaccination as Cardiovascular Prevention in Adults with Heart Disease.Cardiovascular drugs and therapy · 2026Review
- Varicella zoster virus infection.Nature reviews. Disease primers · 2026Review
- A Cross-Sectional Seroepidemiological Study on Varicella Zoster Virus in Zhejiang, China.Vaccines · 2026Article
- Epidemiological characteristics of varicella in Xuzhou from 2015 to 2024: surveillance study.BMC infectious diseases · 2026Article
- Article
- Evaluating varicella-zoster virus vaccine immunogenicity through Fc-mediated antibody functions: the roles of ADCP and ADCC.NPJ vaccines · 2026Article
- A Stepwise Household Transmission of Vaccine-Strain Varicella-Zoster Virus Resulting in Neonatal Varicella.Infection & chemotherapy · 2026Article
- Seroepidemiological Study of Varicella Zoster Virus in Korea, 2023.Journal of Korean medical science · 2026Article
- Article
- Modeling the clinical and economic impact of universal varicella vaccination in Belgium with dynamic population.PLOS global public health · 2026Article
- Herpes zoster frequency and severity in immunocompromised pediatric populations: a structured narrative review.Frontiers in pediatrics · 2026Review
- Seroepidemiological survey of the population 10 years after the implementation of the varicella vaccine 2-dose immunization strategy.Human vaccines & immunotherapeutics · 2025Article
- Hemichorea as a primary manifestation of varicella-zoster virus neuroinfection in a child - a case report and review of literature.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- The Gut Microbiome in Enteric Viral Infections: Underlying Mechanisms and Therapeutic Approaches.Microorganisms · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Varicella (chickenpox) is an infectious disease caused by the highly contagious varicella zoster virus with a secondary attack rate greater than 90%. From this perspective, we aimed to establish the basis for a national varicella vaccine policy by reviewing vaccination programs and policies of countries that have introduced universal varicella vaccinations. As a result of the spread of varicella, an increasing number of countries are providing 2-dose vaccinations and universally expanding their use. In practice, the efficacy and effectiveness of vaccination differ among vaccines and vaccination programs. Optimized vaccination strategies based on each country's local epidemiology and health resources are required. Accordingly, it is necessary to evaluate the effectiveness of varicella vaccines in different settings. Given the short-term and fragmented vaccine effectiveness evaluation in Korea, it is necessary to evaluate its effectiveness at the national level and determine its schedule based on the evidence generated through these studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.